Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here you go bud. DRYWORLD BRANDS LONG💰
https://www.finra.org/investors/insights/corporate-actions-public-companies-what-you-should-know
Pretty sure this won’t be an issue now.😎💰
The market capitalization rule is a rule set by the New York Stock Exchange (NYSE) to determine a minimum market value for a company to continue to be listed on the exchange. The market capitalization rule states that companies must maintain a minimum market cap of $15 million over a consecutive 30-day trading period.
BOOOOOOOM!! Here we go😎
Yeah man!! DRYWORLD BRANDS LONG💰
Last fall, DRYWORLD acquired the Brio Holding Group, Inc., opening access to retail distribution across more than 9,000 locations in Brazil, Columbia, Costa Rica, Ecuador, Panama and Peru. This acquisition is opening up the soccer team kit deals in the region with an update on a deal closing expected imminently.
Notably, the company notched 1,700% growth in Q1 2024 sales as compared to the same period in 2023.
DRYWORLD BRANDS CORPORATE UPDATE💰💰💰💰
SANTA BARBARA, CA / ACCESSWIRE / March 5, 2024 / DRYWORLD Brands Inc. (OTC PINK:IBGR), a premium performance sports brand, today shared a corporate update highlighting its growth in 2023 and the company's outlook for 2024. Notably, the company notched 1,700% growth in Q1 2024 sales as compared to the same period in 2023.
In 2024, DRYWORLD plans to further expand existing operations by opening new sales and distribution channels for current and future partners in strategic territories. The company continues to negotiate with top athletes, sports teams and leagues worldwide and welcomes a variety of sports and individuals to its purpose-driven mission "for athletes, by athletes." In addition, DRYWORLD is focused on uplisting to the OTCQB with a new ticker symbol in 2024.
DRYWORLD remains focused on addressing shareholder issues and improving its corporate structure. This includes aligning its corporate name and ticker symbol with current operations and uplisting to the OTCQB market. DRYWORLD's legal and audit teams are working hard to advance through the required regulatory processes on both issues, and the necessary two-year financial audit is well underway.
"2024 is set to be a milestone year for DRYWORLD as we continue to stack up revenue streams by closing global deals such as PFC Beroe x Ronaldinho, and our Super Rugby partnership, aligning our company with the top athletes, teams and leagues in the world. DRYWORLD faced a number of challenges in 2023 but we believe we have largely worked through these, and our sole focus is now on elevating our brand, driving revenue, increasing the fundamentals of the company and building long-term shareholder value.
"Finally, I want to thank all of our shareholders. We appreciate your continued support and look forward to updating you on our progress throughout the year," said DRYWORLD Co-CEO, Matt Weingart.
In the past two-plus years, DRYWORLD's ecommerce business has launched 377 products and shipped to nearly 1,000 customers across six continents and 53 countries, showcasing its global appeal. Revenue in this area for January 2024 increased more than 227% compared to January 2023, due to Ambassador Program.
DRYWORLD's management team increased the authorized number of shares of common stock to 980,000,000 to accommodate capital raising efforts, and intends to continue to raise capital on an as-needed basis to minimize dilution. Noteholders from a financing in September 2021 have converted a portion of their notes into common stock, pursuant to the terms of their agreements.
The Company can confirm that Management has not sold any shares and further, that it is not permitted to sell any shares until the company is fully reporting and the shares are registered with the SEC, and even at that point, management will still be required to file all the appropriate paperwork which would become publicly available information.
Recent Operational Highlights
DRYWORLD extended its deal with soccer legend Ronaldinho for another 10 years, leading to the signing of PFC Beroe, a Bulgarian club known as "The Greens," and locking in a contractually obligated minimum annual order of $215,000 for the youth academy and fan merchandise.
DRYWORLD Super League Triathlon and DRYWORLD are negotiating a contract extension to their current three-year deal after a successful first two years that have garnered the brand a combined $68 million in media value and sponsorship value of nearly $17 million with nearly 100 million cumulative global viewers and close to 20,000 hours of global coverage.
Management continues to work towards the completion of its partnership in China to allow for expansion in the region. An agreement has been reached in principle, and will be signed on completion of a licensing agreement with the current operator of the brand in China.
After signing a letter of intent to acquire the RESET SYSTEM method of training movement, DRYWORLD is working with its factory partner to build the updated market-ready product, at which time the IP transfer and a global launch will take place.
DRYWORLD delivered its first order for its recently announced New Zealand Super Rugby Clubs partnership and the e-commerce store has launched, featuring co-branded DRYWORLD compression gear with a range of New Zealand Super Rugby licensed products.
Last fall, DRYWORLD acquired the Brio Holding Group, Inc., opening access to retail distribution across more than 9,000 locations in Brazil, Columbia, Costa Rica, Ecuador, Panama and Peru. This acquisition is opening up the soccer team kit deals in the region with an update on a deal closing expected imminently.
The company launched its D Ambassador Program in August 2023 with nine Super League Triathlon athletes, where athletes become shareholders, in nine countries and three continents, making it one of the largest ambassador deals by a single brand in the sport of triathlon. The D Ambassador Program has since increased 411% since launching five months ago and is now onboarding 45 athletes from Europe, LATAM, the UK and the United States. The program has been effective and is performing as expected in driving revenue, with January 2024 eCom revenue up 227% as compared to January 2023.
Also in 2023, DRYWORLD entered the world of NCAA sports by signing one of the largest NIL (name, image, likeness) deals in its history, initially launching merchandise programs with Sofia Chepenik, a University of South Florida lacrosse player, and Trente Jones, a University of Michigan football player. The NIL athlete merchandise programs are a first of their kind.
DRYWORLD expanded its philanthropic giving by supporting Curley Boo Johnson's Basketball Camp, Mode Ghana Basketball Camp and the Athens Women's Football Summit.
The company is positioning itself as a thought leader in the field of athletic performance, and has published 91 posts on its D Word Power of One blog, including tips, tricks, and insights for athletes on how to improve their physical and mental performance.
With a focus on updating shareholders and key stakeholders, DRYWORLD recently engaged PCG Advisory, Inc., a leading firm specializing in investor relations and digital strategies, to advise on the growing company's global investment outreach and strategic communications.
About DRYWORLD
DRYWORLD is a premium performance sports brand offering innovative, superior quality apparel and gear for the athlete in all of us. We build purpose-driven products that give all athletes the edge. Engineered by athletes, proven by science. For more information, visit dryworldshop.com.
8-K out about yesterday’s news!! Let’s go NYSE😎💰
https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/0001407973/000095017024024997/sonx-20240301.htm
NYSE news has to be coming, and soon😎💰
NYSE here we come!! SONX LONG💰
Excellent news😎💰
SONX NEWS💰
Sonendo, Inc. (OTCQX: SONX) (“Sonendo” or the “Company”), a leading dental technology company and developer of the GentleWave® System, announced today that it has executed a definitive agreement for the sale of its Software Segment assets comprised of TDO Software, to Valsoft Corporation Inc. ("Valsoft"), a Quebec company based in Montreal specializing in the acquisition and development of vertical market software businesses. In addition, Sonendo announced that it has reached an agreement with Perceptive Credit Holdings, LP to amend its Amended and Restated Credit Agreement and Guaranty, dated as of August 23, 2021, as amended (“Perceptive Loan").
TDO Software is a developer of widely used endodontic practice management software solutions, designed to simplify practice workflow. TDO® Software integrates practice management, imaging, referral reporting and cone beam computed tomography imaging, and offers an integrated communication system with Sonendo's GentleWave® System.
The sale of the TDO assets is effective March 1, 2024, and provides for total gross consideration of approximately $16.0 million, with $15.0 million paid upon closing and the balance due in approximately 12 months pursuant to the terms of the agreement. The amendment to the Perceptive Loan includes a one-time $15.0 million principal repayment and initiates monthly principal repayments beginning in March 2024 along with modifications to certain other terms including revenue covenants.
“Today’s announcements reflect Sonendo’s commitment to balancing responsible cash preservation while pursuing long-term growth opportunities for the GentleWave system,” said Bjarne Bergheim, President and CEO of Sonendo. “TDO is a great technology, and we look forward to continued partnership with the team at Valsoft. Moving forward, this divestiture allows Sonendo to focus solely on growing awareness and adoption of the GentleWave procedure. At the same time, we know TDO users will be in great hands with Valsoft’s focus on furthering the TDO practice management software platform.”
“We are thrilled to welcome TDO to Valsoft,” said Gianni Farruggia, Valsoft Operating Partner. “TDO joining our Health & Dental portfolio is a milestone in our commitment to innovation and excellence in dental healthcare technology. TDO's dedication to the endodontic community align perfectly with our vision. We look forward to leveraging TDO’s endodontic practice management expertise to enhance and expand the solutions we offer to the health and dental industry.”
Stifel served as the exclusive financial advisor to Sonendo, and Reed Smith LLP acted as legal counsel to Sonendo. Valsoft represented themselves in the transaction.
Yeah, those assholes are good at replenishing shares on the ASK unfortunately, our day will be coming soon.😎
.0115😎 DRYWORLD BRANDS💰
DRYWORLD BRANDS WINNING💰💰💰💰
Jeff Ramson, CEO and founder of PCG Advisory, added, "DRYWORLD has a unique position in the market with its innovative approach to athletic wear, captivating athletes worldwide. The brand's ongoing growth and strategic partnerships enhance its appeal and market presence. We look forward to sharing their innovation, expansion efforts and value proposition with the investment community."
PLEASE bring the SEC here, so they can see the DAILY commitment to bringing the share price down.🤣 Absolutely ridiculous LMAO! DRYWORLD BRANDS is taking off with or without the nonsense!
Agreed bud! I’ll take either one.😎💰
LMAO! No one wants to state the OBVIOUS fact that EVERYONE could’ve sold between .50-.735 and made a killing! Comical to say the least! DRYWORLD BRANDS LONG💰
No doubt about that bud😎 They’ll be drooling soon🤣 DRYWORLD BRANDS WINNING💰
Those BEARS get awful quiet when DRYWORLD BRANDS is up 56.67%🤣😎
We gotta be close bud😎💰
That’s what she said🤣 DRYWORLD BRANDS LONG💰
Looking forward to it😎💰
Nice movement here today!! Up 56.67%😎
Back over .01 for power hour😎 DRYWORLD BRANDS💰
HUGE BIDS coming in now😎 DRYWORLD BRANDS LONG💰
It’s trading, and there’s currently a BID for over $16,000😎 SONX LONG💰
10-K due soon. Let’s go TEAM SONX💰
As of December 31, 2023, Virios Therapeutics’ cash totaled $3.3 million. The Company believes it has sufficient resources to fund operations into the fourth quarter of 2024.
When it’s all said and done, the BASHERS will have accomplished NOTHING😎 DRYWORLD BRANDS LONG💰
The SPV of Operations just bought 62,568!! VIRI LONG💰
https://www.sec.gov/Archives/edgar/data/1818844/000141588924005670/xslF345X05/form4-02282024_050234.xml
The CMO just bought 88,085!! VIRI LONG💰
https://www.sec.gov/Archives/edgar/data/1818844/000141588924005668/xslF345X05/form4-02282024_050208.xml
Greg Duncan(CEO) just purchased 138,835 shares two days ago!! VIRI LONG💰
IMC-2 Long-COVID Development Program: We have clarity from the Food and Drug Administration (“FDA”) on the development requirements for advancing IMC-2 (combination of valacyclovir and celecoxib) into Phase 2 development as a treatment for LC symptoms. As noted above, we expect to receive top line results from the ongoing Bateman Horne Center independent investigator supported study in the second half of 2024. There continues to remain a high unmet medical need for treating LC symptoms. Recently, a USA Today Health article reported that federal estimates suggest at least 16 million Americans have LC and as many as 4 million of them are disabled by it. There are currently no FDA approved LC treatments. We are excited that IMC-2 has the potential to be one of the first approved treatments for LC and are exploring various means by which to fund execution of the important Phase 2b IMC-2 trial.
IMC-1 Fibromyalgia Development Program: We reached alignment with the FDA on the IMC-1 (combination of famciclovir and celecoxib) Phase 3 development program for treatment of fibromyalgia. We continue to be engaged with potential external entities who have an interest in partnering for this important program.
The Virios team remains committed to delivering on the promise of combination antiviral therapy to address a multitude of serious health issues and illnesses. We appreciate your support.
February 27, 2024
Dear Virios (VIRI) Shareholders,
On behalf of the Virios directors and the executive team, we would like to provide a corporate progress report on several key topics as we proceed through the first quarter of 2024.
Special Shareholder Meeting: On March 1, 2024, we will hold a special shareholder meeting, whereby we are requesting your approval to execute a reverse stock split some time over the course of the next 12 months. In our outreach to shareholders in connection with the meeting, we heard concerns about whether and when the reverse stock split would be implemented, if approved, and we want to address those concerns here. Approval of this proposal does not commit the Company to the execution of a reverse stock split. It does provide maximum strategic optionality moving forward, including the ability to execute strategic transactions and to enable future fund raising.
Indeed, the Board’s unanimous view is that the implementation of the reverse stock split should be deferred until after the Company has clarity on the results of the current Long-COVID (“LC”) study being independently run via an unrestricted grant to the Bateman Horne Center. Results from this study are currently projected to be reported in the second half of 2024.
Director Fee and Management Team 10% Salary Cut: We work diligently to minimize operational expenses and deploy our cash to fund value creating research as evidenced by the fact that we operate VIRI as a public company with four full-time employees. In order to underscore the management team’s alignment as fellow shareholders and to emphasize our commitment to long-term success and value creation, all of Virios’ employees have agreed to a 10% salary compensation reduction in exchange for future vesting stock options. In addition, our directors have also agreed to a 10% reduction in cash director fees.
IMC-2 Long-COVID Development Program: We have clarity from the Food and Drug Administration (“FDA”) on the development requirements for advancing IMC-2 (combination of valacyclovir and celecoxib) into Phase 2 development as a treatment for LC symptoms. As noted above, we expect to receive top line results from the ongoing Bateman Horne Center independent investigator supported study in the second half of 2024. There continues to remain a high unmet medical need for treating LC symptoms. Recently, a USA Today Health article reported that federal estimates suggest at least 16 million Americans have LC and as many as 4 million of them are disabled by it. There are currently no FDA approved LC treatments. We are excited that IMC-2 has the potential to be one of the first approved treatments for LC and are exploring various means by which to fund execution of the important Phase 2b IMC-2 trial.
IMC-1 Fibromyalgia Development Program: We reached alignment with the FDA on the IMC-1 (combination of famciclovir and celecoxib) Phase 3 development program for treatment of fibromyalgia. We continue to be engaged with potential external entities who have an interest in partnering for this important program.
The Virios team remains committed to delivering on the promise of combination antiviral therapy to address a multitude of serious health issues and illnesses. We appreciate your support.